訊聯生技集團 創立於1999年，訊聯生技以「25年AIｘ外泌體．精準健康．再生醫學領導品牌」為核心，成為亞洲領先的生技品牌。

集團旗下企業

• 訊聯生技股份有限公司 (1784)：1999年成立，台灣第一家幹細胞上市櫃公司。

• 訊聯基因數位股份有限公司 (4160)：2008年成立，台灣第一家精準健康與數位科技上市櫃公司。

• 訊聯細胞智藥股份有限公司 (7808)：2022年成立，通過「生技醫藥」資格審定，首創外泌體技術與AI智慧研發，2024年12月登錄興櫃。

我們的影響力

• 與數千家業者攜手共創AI外泌體再生醫學產業新局。

• 服務全台50%新生兒與95%婦產科及生殖醫學中心。

• 與500+醫療機構合作，協助幹細胞移植份數逾850份，應用疾病超過70項以上。

• 業務拓展至17個國家，服務超過180萬名客戶。

主要成就

• 獲台灣衛福部核准63項細胞治療計畫

    1. 脂肪間質幹細胞用於退化性關節炎、膝關節軟骨缺損、慢性傷口、皮下及軟組織缺損

    2. 免疫細胞CIK治療大腸直腸癌、肺癌、乳癌、肝癌等多種實體癌症。

• 脂肪幹細胞治療獲准數、收案人數全台領先，達全台收案量8成。

BIONET Corp.

BIONET Corp. – 25 Years of Leadership in AI-Driven Exosome Technology, Precision Health, and Regenerative Medicine, Pioneering Biotech Innovation in Asia.

Our Companies

• BIONET Corp. (1784): Founded in 1999, Taiwan’s first publicly listed stem cell company.

• GGA Corp. (4160): Founded in 2008, Taiwan’s first publicly listed company specializing in precision health and digital technology.

• BIONET Therapeutics Corp. (7808): Founded in 2022, officially recognized under the "Biotechnology and Pharmaceutical" qualification review. The first company to pioneer Exosome technology and AI-driven research, set to be listed on the Emerging Stock Board in December 2024.

Our Impact

• Collaborating with thousands of enterprises to drive AI-Exosome regenerative medicine innovation.

• Providing services to 50% of newborns and 95% of gynecology and reproductive centers in Taiwan.

• Partnering with 500+ medical institutions, facilitating over 850 stem cell transplants across 70+ disease applications.

• Expanding operations to 17 countries, serving over 1.8 million customers worldwide.

Our Achievements

• 63 approved cell therapy projects under Taiwan's Ministry of Health and Welfare, including treatments utilizing adipose-derived mesenchymal stem cells for degenerative arthritis, knee cartilage defects, and chronic wounds, Subcutaneous and Soft Tissue Defects , as well as immune cell (CIK) therapy for colorectal cancer, lung cancer, breast cancer, liver cancer, and more.

• Leading the market in adipose-derived stem cell therapy, with 80% of nationwide patient enrollment and approvals.